Cable Hill Partners’s BioLineRX BLRX Stock Holding History

Cable Hill Partners’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5	Closed	-$3K	–	890
2018 Q1	$3K	Hold	5	–	–	﹤0.01%	758
2017 Q4	$3K	Hold	5	–	–	﹤0.01%	811
2017 Q3	$3K	Buy	+5	New	+$3.11K	﹤0.01%	856

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cable Hill Partners's BLRX Position: Q2 2018 in Review

Cable Hill Partners sold out of BioLineRX (BLRX) in Q2 2018, closing a stake of 5 shares — an estimated $3K sold.

Cable Hill Partners first reported a position in BLRX in Q3 2017 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 25 funds tracked by Wall St. Rank hold BLRX as of Q2 2018.

Cable Hill Partners reported no remaining BioLineRX position as of Q2 2018 after selling out during the quarter.
Cable Hill Partners sold 5 BioLineRX shares in Q2 2018, an estimated $3K.
Cable Hill Partners first reported a position in BioLineRX in Q3 2017 and held it in 3 quarters.
Cable Hill Partners's BioLineRX position peaked at $3K in Q1 2018.
25 funds tracked by Wall St. Rank held BioLineRX as of Q2 2018.

Based on Cable Hill Partners's 13F filing for Q2 2018, filed 3 Aug 2018.